BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 22761793)

  • 1. MALDI imaging mass spectrometry for in situ proteomic analysis of preneoplastic lesions in pancreatic cancer.
    Grüner BM; Hahne H; Mazur PK; Trajkovic-Arsic M; Maier S; Esposito I; Kalideris E; Michalski CW; Kleeff J; Rauser S; Schmid RM; Küster B; Walch A; Siveke JT
    PLoS One; 2012; 7(6):e39424. PubMed ID: 22761793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In situ proteomic analysis by MALDI imaging identifies ubiquitin and thymosin-β4 as markers of malignant intraductal pancreatic mucinous neoplasms.
    Rebours V; Le Faouder J; Laouirem S; Mebarki M; Albuquerque M; Camadro JM; Léger T; Ruszniewski P; Lévy P; Paradis V; Bedossa P; Couvelard A
    Pancreatology; 2014; 14(2):117-24. PubMed ID: 24650966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Annexin A10 is a candidate marker associated with the progression of pancreatic precursor lesions to adenocarcinoma.
    Zhu J; Wu J; Pei X; Tan Z; Shi J; Lubman DM
    PLoS One; 2017; 12(4):e0175039. PubMed ID: 28369074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. mAb Das-1 identifies pancreatic ductal adenocarcinoma and high-grade pancreatic intraepithelial neoplasia with high accuracy.
    Das KK; Brown JW; Fernandez Del-Castillo C; Huynh T; Mills JC; Matsuda Y; Das KM; Mino-Kenudson M
    Hum Pathol; 2021 May; 111():36-44. PubMed ID: 33524436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative assessment of pancreatic cancer precursor lesions in IHC-stained tissue with a tissue image analysis platform.
    Aeffner F; Martin NT; Peljto M; Black JC; Major JK; Jangani M; Ports MO; Krueger JS; Young GD
    Lab Invest; 2016 Dec; 96(12):1327-1336. PubMed ID: 27775692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteomic analysis to identify biomarker proteins in pancreatic ductal adenocarcinoma.
    Chung JC; Oh MJ; Choi SH; Bae CD
    ANZ J Surg; 2008 Apr; 78(4):245-51. PubMed ID: 18366394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a Class Prediction Model to Discriminate Pancreatic Ductal Adenocarcinoma from Pancreatic Neuroendocrine Tumor by MALDI Mass Spectrometry Imaging.
    Casadonte R; Kriegsmann M; Perren A; Baretton G; Deininger SO; Kriegsmann K; Welsch T; Pilarsky C; Kriegsmann J
    Proteomics Clin Appl; 2019 Jan; 13(1):e1800046. PubMed ID: 30548962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of Small Proteins and Peptides in the Differentiation of Patients with Intraductal Mucinous Neoplasms of the Pancreas, Chronic Pancreatitis and Pancreatic Adenocarcinoma.
    Fania C; Pezzilli R; Melzi d'Eril G; Gelfi C; Barassi A
    Dig Dis Sci; 2018 Apr; 63(4):920-933. PubMed ID: 29417328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of the pancreatic tumor progression by a quantitative proteomic approach and immunhistochemical validation.
    Sitek B; Sipos B; Alkatout I; Poschmann G; Stephan C; Schulenborg T; Marcus K; Lüttges J; Dittert DD; Baretton G; Schmiegel W; Hahn SA; Klöppel G; Meyer HE; Stühler K
    J Proteome Res; 2009 Apr; 8(4):1647-56. PubMed ID: 19714807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serine protease inhibitor Kazal type 1 and epidermal growth factor receptor are expressed in pancreatic tubular adenocarcinoma, intraductal papillary mucinous neoplasm, and pancreatic intraepithelial neoplasia.
    Ozaki N; Ohmuraya M; Ida S; Hashimoto D; Ikuta Y; Chikamoto A; Hirota M; Baba H
    J Hepatobiliary Pancreat Sci; 2013 Aug; 20(6):620-7. PubMed ID: 23475261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of pancreatic cancer tumours and precursor lesions by cathepsin E activity in mouse models.
    Cruz-Monserrate Z; Abd-Elgaliel WR; Grote T; Deng D; Ji B; Arumugam T; Wang H; Tung CH; Logsdon CD
    Gut; 2012 Sep; 61(9):1315-22. PubMed ID: 22068166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification and verification of transthyretin as a potential biomarker for pancreatic ductal adenocarcinoma.
    Chen J; Chen LJ; Xia YL; Zhou HC; Yang RB; Wu W; Lu Y; Hu LW; Zhao Y
    J Cancer Res Clin Oncol; 2013 Jul; 139(7):1117-27. PubMed ID: 23546595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrated expression profiling of potassium channels identifys KCNN4 as a prognostic biomarker of pancreatic cancer.
    Jiang S; Zhu L; Yang J; Hu L; Gu J; Xing X; Sun Y; Zhang Z
    Biochem Biophys Res Commun; 2017 Dec; 494(1-2):113-119. PubMed ID: 29050937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of kallikrein-related peptidase 7 predicts poor prognosis in patients with unresectable pancreatic ductal adenocarcinoma.
    Iakovlev V; Siegel ER; Tsao MS; Haun RS
    Cancer Epidemiol Biomarkers Prev; 2012 Jul; 21(7):1135-42. PubMed ID: 22573795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential ezrin and phosphorylated ezrin expression profiles between pancreatic intraepithelial neoplasia, intraductal papillary mucinous neoplasm, and invasive ductal carcinoma of the pancreas.
    Oda Y; Aishima S; Morimatsu K; Hayashi A; Shindo K; Fujino M; Mizuuchi Y; Hattori M; Tanaka M; Oda Y
    Hum Pathol; 2013 Aug; 44(8):1487-98. PubMed ID: 23465281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. KRAS2 mutations in human pancreatic acinar-ductal metaplastic lesions are limited to those with PanIN: implications for the human pancreatic cancer cell of origin.
    Shi C; Hong SM; Lim P; Kamiyama H; Khan M; Anders RA; Goggins M; Hruban RH; Eshleman JR
    Mol Cancer Res; 2009 Feb; 7(2):230-6. PubMed ID: 19208745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histologic characteristics of pancreatic intraepithelial neoplasia associated with different pancreatic lesions.
    Recavarren C; Labow DM; Liang J; Zhang L; Wong M; Zhu H; Wang J; Francis F; Xu R
    Hum Pathol; 2011 Jan; 42(1):18-24. PubMed ID: 21056895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distinction of Invasive Carcinoma Derived From Intraductal Papillary Mucinous Neoplasms From Concomitant Ductal Adenocarcinoma of the Pancreas Using Molecular Biomarkers.
    Tamura K; Ohtsuka T; Date K; Fujimoto T; Matsunaga T; Kimura H; Watanabe Y; Miyazaki T; Ohuchida K; Takahata S; Ishigami K; Oda Y; Mizumoto K; Nakamura M; Tanaka M
    Pancreas; 2016 Jul; 45(6):826-35. PubMed ID: 26646266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differentiation of pancreatic ductal adenocarcinoma from chronic pancreatitis by PAM4 immunohistochemistry.
    Shi C; Merchant N; Newsome G; Goldenberg DM; Gold DV
    Arch Pathol Lab Med; 2014 Feb; 138(2):220-8. PubMed ID: 24476519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteomic analysis of pancreatic intraepithelial neoplasia and pancreatic carcinoma in rat models.
    Wang L; Liu HL; Li Y; Yuan P
    World J Gastroenterol; 2011 Mar; 17(11):1434-41. PubMed ID: 21472101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.